Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02663921 · ClinicalTrials.gov registry record · NA
Visible Light Study
A NA study of Skin Disease and Pigment Disorders, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT02663921 is a NA study of Skin Disease and Pigment Disorders that has completed, run by NYU Langone Health. The registered enrollment target is 8 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02663921, a NA study of Skin Disease and Pigment Disorders, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn more about the potential effects of visible light on the skin. More specifically, this study will examine whether an incandescent lamp (light bulb) or LED light bulb can cause skin to become darker. Investigators will determine the minimum threshold dose required to achieve immediate pigmentation darkening (IPD), persistent pigmentation darkening (PPD), and delayed tanning (DT) for Fitzpatrick skin types IV - VI utilizing two visible light sources.
Conditions Studied
Interventions
- OTHER Part A: Baseline-Week 2
- OTHER Part B: Week 4-Week 12
Study Locations (1)
New York
- New York University School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-09 |
| Est. Completion | 2019-04-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02663921
The ClinicalTrials.gov registry entry for NCT02663921 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Skin Disease appearing as the primary indexed condition, and to 2 interventions - of which Part A: Baseline-Week 2 is the first listed.
NCT02663921 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02663921 about?
NCT02663921 is a clinical study titled "Visible Light Study". The purpose of this study is to learn more about the potential effects of visible light on the skin. More specifically, this study will examine whether an incandescent lamp (light bulb) or LED light bulb can cause skin to become darker. Investigators will determine the minimum threshold dose require...
What is the current status of trial NCT02663921?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2015-09. Estimated completion is 2019-04-17.
What conditions does trial NCT02663921 study?
This clinical trial studies the following conditions: Skin Disease, Pigment Disorders.
What interventions are being tested in trial NCT02663921?
The interventions under investigation include: Part A: Baseline-Week 2 (OTHER), Part B: Week 4-Week 12 (OTHER).
Who is sponsoring clinical trial NCT02663921?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02663921 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.